FFO
VRDN icon

Fortitude Family Office’s Viridian Therapeutics VRDN Stock Holding History

Fortitude Family Office’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17
Closed -$333 – 2384
2026
Q1 		$333 Buy
+17
New +$505 ﹤0.01% 1815
2025
Q2 		– Sell
-38
Closed -$512 – 2146
2025
Q1 		$512 Hold
38
– – ﹤0.01% 1078
2024
Q4 		$728 Hold
38
– – ﹤0.01% 1179
2024
Q3 		$865 Buy
+38
New +$621 ﹤0.01% 1116
2024
Q2 		– Sell
-29
Closed -$508 – 1061
2024
Q1 		$508 Hold
29
– – ﹤0.01% 930
2023
Q4 		$632 Buy
+29
New +$458 ﹤0.01% 969

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fortitude Family Office's VRDN Position: Q2 2026 in Review

Fortitude Family Office sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 17 shares — an estimated $333 sold.

Fortitude Family Office first reported a position in VRDN in Q4 2023 and held it in 6 quarters. The position peaked at $865 in Q3 2024. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Fortitude Family Office reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fortitude Family Office sold 17 Viridian Therapeutics shares in Q2 2026, an estimated $333.
  • Fortitude Family Office first reported a position in Viridian Therapeutics in Q4 2023 and held it in 6 quarters.
  • Fortitude Family Office's Viridian Therapeutics position peaked at $865 in Q3 2024.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.